Cystic fibrosis (CF) is a life-limiting genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, primarily affecting the lungs and digestive system. As survival rates improve, the CF population ages, and the prevalence of cystic fibrosis-related diabetes (CFRD) rises sharply—affecting roughly 20% of adolescents and 40–50% of adults. CFRD is a distinct form of diabetes that shares features of both type 1 and type 2 diabetes but is fundamentally different from either. The primary driver is progressive scarring and destruction of pancreatic islet cells due to thick, viscous secretions, leading to impaired insulin secretion. Over time, insulin deficiency becomes more pronounced. Additionally, many individuals with CF also develop insulin resistance, especially during periods of acute illness, inflammation, or high-dose corticosteroid therapy. This dual pathology means that CFRD can present with both fasting hyperglycemia and severe post‑prandial glucose excursions.

Symptoms of CFRD often overlap with CF itself—fatigue, weight loss, poor growth, and unexplained decline in lung function can all be due to uncontrolled diabetes. Classic diabetes symptoms such as polyuria and polydipsia may be masked or attributed to CF medications. For this reason, annual oral glucose tolerance testing (OGTT) is recommended for all individuals with CF aged 10 years and older. Early detection is critical because even mild hyperglycemia can worsen nutritional status and accelerate lung function decline. Once diagnosed, management must be initiated promptly, but the approach must account for the unique metabolic demands of CF, where high‑calorie diets are essential and where the risk of hypoglycemia from insulin can be significant. The interplay between CF and diabetes requires a specialized care model that goes far beyond standard diabetes management.

The Case for a Holistic Approach

Standard diabetes management guidelines are insufficient for CFRD. The primary goal of CFRD therapy is not merely to lower blood glucose but to maintain optimal nutritional status, preserve lung function, and support overall well‑being. A holistic approach acknowledges the interconnectedness of glycemic control, pulmonary health, digestive function, and mental health. It recognizes that CFRD cannot be managed in isolation from the rest of CF care. By addressing the patient as a whole person—rather than a set of organ systems—healthcare providers can create more effective, sustainable, and patient‑centered care plans. This approach requires close collaboration between pulmonologists, endocrinologists, dietitians, pharmacists, psychologists, physical therapists, and nurses, all working together with the patient and family. A truly holistic framework also respects the patient's preferences, cultural background, and social context, making care more adaptable and responsive to individual needs.

Key Components of Holistic CFRD Care

Medical Management

Insulin therapy is the cornerstone of CFRD treatment. Because most patients with CFRD have progressive insulin deficiency, oral agents like metformin are not effective and may have adverse effects on gastrointestinal symptoms. Insulin regimens must be individualized. Many patients do well with a basal‑bolus approach using a long‑acting insulin analogue (e.g., insulin glargine or detemir) for baseline coverage and rapid‑acting insulin (e.g., lispro or aspart) for meals and correction doses. For others, continuous subcutaneous insulin infusion via pump can offer flexibility and improve control, especially when meal patterns are erratic due to CF symptoms. When a patient develops an acute pulmonary exacerbation, insulin requirements often rise due to stress hyperglycemia and corticosteroid use, necessitating close monitoring and dose adjustments.

Glucose monitoring is equally important. Continuous glucose monitoring (CGM) provides real‑time data and trends, helping patients and clinicians identify post‑prandial spikes, nocturnal hypoglycemia, and patterns related to exercise or illness. HbA1c targets are less reliable in CFRD because of altered red blood cell turnover; therefore, time‑in‑range metrics from CGM are preferred. Self‑monitoring of blood glucose (SMBG) remains essential for those who cannot access CGM or need immediate verification. Medical management also extends to optimizing CF therapies—including CFTR modulators, airway clearance techniques, and anti‑inflammatory treatments—because better lung function reduces systemic inflammation and improves insulin sensitivity. The recent introduction of highly effective CFTR modulator therapies such as elexacaftor‑tezacaftor‑ivacaftor has transformed outcomes for many patients; early evidence suggests these agents may improve insulin secretion and delay the onset of CFRD.

Nutritional Support

Nutrition is uniquely challenging in CFRD. Most people with CF require a high‑calorie, high‑fat diet to maintain weight and support lung function. Diabetes management usually encourages carbohydrate restriction, but in CFRD this can lead to weight loss and malnutrition. The solution is a customized diet that focuses on adequate energy intake while controlling post‑prandial glucose excursions. Carbohydrate counting allows patients to match insulin doses to the amount of carbohydrates consumed, and pancreatic enzyme replacement therapy must be optimized to improve digestion and reduce unpredictable absorption. Many patients also benefit from high‑calorie liquid supplements or tube feeding when oral intake is insufficient. Vitamin and mineral deficiencies (especially fat‑soluble vitamins A, D, E, and K) are common and should be monitored and corrected. A registered dietitian specializing in CF is an indispensable member of the care team. The dietitian can also help address electrolyte imbalances that may arise from insulin therapy or CFTR modulation.

Psychological and Emotional Support

Living with both CF and diabetes places an immense burden on patients and families. The daily demands of treatment—multiple insulin injections or pump changes, frequent blood glucose checks, airway clearance, enzyme capsules, and nebulized medications—can lead to burnout, depression, and anxiety. Studies show that depression is more prevalent in people with CFRD compared to those with CF alone, and it is associated with poorer adherence and worse glycemic control. Cognitive behavioral therapy, mindfulness interventions, and peer support groups can help patients develop coping strategies. Integrating mental health professionals into the CF care team normalizes psychological support and reduces stigma. Open communication about emotional challenges should be encouraged, and screening for depression and anxiety using validated tools such as the PHQ-9 or GAD-7 should be part of routine care. Peer support programs specifically for CFRD can be especially powerful, as they allow patients to share experiences of managing two complex conditions simultaneously.

Physical Activity and Pulmonary Rehabilitation

Regular exercise has numerous benefits for people with CFRD: it improves cardiovascular fitness, helps maintain lung function, enhances insulin sensitivity, and aids weight management. However, exercise can also increase the risk of hypoglycemia, especially when insulin is used. Patients need clear guidance on balancing exercise intensity and timing with food intake and insulin dosing. A tailored pulmonary rehabilitation program that incorporates aerobic exercise, strength training, and flexibility can be designed by a physical therapist familiar with CF. Close collaboration between the physical therapist and the diabetes educator ensures that patients can exercise safely and confidently. Many patients also benefit from interval training and resistance exercises, which can improve muscle mass and metabolic health. Exercise regimens should be documented in the care plan, and patients should be taught to adjust their insulin or consume extra carbohydrates before prolonged activity.

Patient and Family Education

Empowerment through education is a pillar of holistic care. Patients and their families must understand the unique nature of CFRD—that it differs from type 1 or type 2 diabetes—and why insulin is the preferred treatment. They need practical skills: how to count carbohydrates, adjust insulin doses for exercise and illness, use a glucometer or CGM, and recognize and treat hypo‑ and hyperglycemia. Education should be ongoing and adapted as the patient grows or as their health changes. Group classes, one‑on‑one sessions with a certified diabetes care and education specialist, and printed or digital materials reinforce learning. Including family caregivers in education sessions helps create a supportive home environment. The use of teach‑back methods can confirm understanding, and digital tools such as smartphone apps can provide reminders and tracking for medications and meals.

Social and Peer Support

Isolation can be a major challenge for individuals with CFRD, partly because the condition is less common than other forms of diabetes. Connecting with others who share the same dual diagnosis can be profoundly validating. The Cystic Fibrosis Foundation offers resources and community connections, and online support groups provide platforms for sharing experiences and tips. Social workers and care coordinators can also help patients navigate insurance, disability benefits, and school or workplace accommodations. For children and adolescents, school nurses should be educated about CFRD to ensure safe management during the school day. Financial advocacy is often needed, as insulin, CGM sensors, and pump supplies can be costly. Peer mentoring programs where experienced CFRD patients guide newly diagnosed individuals can foster resilience and practical knowledge.

Transition of Care

Adolescents and young adults with CFRD face the dual challenge of transitioning from pediatric to adult care while managing a progressive chronic illness. This transition should be planned over several years, with a gradual shift in responsibility from parents to the young adult. Pediatric and adult care teams must communicate clearly, sharing the patient's history, current regimen, and psychosocial needs. A transition coordinator, often a nurse or social worker, can help facilitate appointments, ensure continuity of insurance, and provide emotional support. Young adults should be encouraged to take ownership of their diabetes tasks, such as ordering supplies, interpreting CGM data, and communicating with their healthcare team. Without a structured transition, adherence and glycemic control often deteriorate, leading to worse outcomes.

The Role of the Multidisciplinary Team

A holistic approach to CFRD cannot succeed without a well‑coordinated multidisciplinary team. The core team typically includes a pulmonologist, endocrinologist, dietitian, diabetes educator, social worker, pharmacist, and mental health professional. Monthly or quarterly case conferences allow team members to discuss each patient’s progress, adjust medications and plans, and address new challenges. Communication between team members must be seamless—for example, if a patient starts a CFTR modulator, the endocrinologist must be informed because improved CFTR function can alter insulin requirements. Care coordination should also extend to primary care providers and any specialists involved in managing CF complications such as liver disease or osteoporosis. Team members should share a common understanding of CFRD pathophysiology and treatment goals to avoid conflicting advice. In many centers, a designated CFRD clinic session brings all providers together for same‑day appointments, reducing the burden on patients.

Challenges in Implementing Holistic Care

Despite the clear benefits, practical barriers hinder the widespread adoption of holistic CFRD care. Time constraints in clinical settings limit the ability of providers to address every component comprehensively. Reimbursement for services such as diabetes education, CGM, and mental health counseling varies by region and payer. Additionally, some patients may be reluctant to take on more treatment burden or may lack the support systems needed to follow complex regimens. Overcoming these challenges requires systemic changes—such as integrating care models, using telehealth to increase access, and advocating for insurance parity for CFRD‑specific supplies and services. Clinicians should also use a shared decision‑making approach, respecting each patient’s readiness and goals. Flexibility in scheduling and the use of patient portals can improve engagement. Research is needed to develop implementation strategies that work in resource‑limited settings, including nurse‑led clinics and community health worker support.

Monitoring Outcomes in CFRD

Tracking the success of holistic CFRD care requires a broader set of metrics than blood glucose alone. Key clinical outcomes include pulmonary function (FEV₁), body mass index (BMI), number of pulmonary exacerbations per year, and glycemic measures such as time‑in‑range and HbA1c (interpreted cautiously). Patient-reported outcomes, including quality of life scores, diabetes distress, and treatment satisfaction, provide invaluable insight into whether the care plan is truly meeting the patient’s needs. Regular assessment of microvascular complications (retinopathy, nephropathy, neuropathy) is indicated for patients with CFRD of longer duration. The multidisciplinary team should review these data at regular intervals and adjust the care plan accordingly. Benchmarking against CF registry data can help centers identify areas for improvement and share best practices.

Future Directions

The landscape of CFRD care continues to evolve. CFTR modulator therapies, such as elexacaftor‑tezacaftor‑ivacaftor, have dramatically improved lung function and nutritional status for many patients, and early evidence suggests they may also improve insulin secretion and delay the onset of CFRD. Future research will likely focus on precision medicine approaches—tailoring insulin regimens and monitoring strategies based on genetic background, CGM patterns, and inflammatory markers. Digital health tools, including smartphone apps that integrate CGM data with diet logs and activity trackers, hold promise for real‑time decision support. Additionally, efforts to standardize CFRD care through clinical guidelines—such as those published by the American Diabetes Association—help raise awareness and improve consistency across centers. Ongoing trials are exploring the role of newer insulin formulations, hybrid closed‑loop systems, and adjunctive non‑insulin therapies in CFRD. The ultimate goal is to integrate these advances into a holistic framework that remains centered on the patient.

Conclusion

Developing a holistic approach to cystic fibrosis diabetes care is essential for meeting the complex needs of this growing patient population. By integrating advanced medical management with nutritional, psychological, physical, educational, and social support, healthcare teams can help patients with CFRD achieve better health outcomes and a more fulfilling life. The challenge lies in implementing this vision within resource‑constrained healthcare systems, but the rewards—improved lung function, nutritional stability, and enhanced quality of life—make the effort worthwhile. As therapies for CF continue to advance, a truly holistic framework will remain the bedrock of effective CFRD care, empowering patients to thrive despite the dual demands of their condition. For further reading, the Cystic Fibrosis Foundation Clinical Care Guidelines for CFRD provide comprehensive recommendations.